Sponsor Check › Person
Related person on Form D filings · address states as listed: PA, NY, TX · listed Mar 14, 2012 → Jul 18, 2018
Data last updated: Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 23, 2026, 11:59 PM ET · SEC enforcement last checked: not yet
Privacy: business-related public information only. Residential addresses are never shown; only the state from the filing.
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
None found in sources searched.
Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30) — federal district + bankruptcy courts; live RECAP re-check pending. State courts: not yet searched. PACER: not searched. · Last checked Oct 23, 2026, 11:59 PM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — not yet searched; State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.
Not yet searched.
No SEC search has run yet for this person.
None found in sources searched.
Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Last checked Oct 23, 2026, 11:59 PM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
Comparisons are made for sponsors and sponsor groups, not individual people.
2 of 10 offerings report sales commissions totalling $1,569,634; 1 reports finder's fees totalling $67,880; 3 report proceeds to related persons totalling $2,000,000. (includes amounts the issuer reported as estimates)
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | Dec 30, 2022 D File 021-469329 | $319,634 (est.) | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 3, 2020 D File 021-368196 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 3, 2019 D/A File 021-354370 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 19, 2019 D File 021-353767 | $0 | $0 | $400,000 | None listed on this filing |
| EDGAR ↗ | Jul 18, 2018 D File 021-317168 | $0 | $0 | $850,000 (est.) | None listed on this filing |
| EDGAR ↗ | Aug 15, 2017 D File 021-292798 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 15, 2017 D File 021-292800 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 20, 2017 D/A File 021-252193 | $1,250,000 (est.) | $0 | $750,000 (est.) | MTS Securities, LLC BrokerCheck CRD 104059 ↗ William Blair & Company BrokerCheck CRD 1252 ↗ |
| EDGAR ↗ | Mar 14, 2013 D/A File 021-174950 | $0 | $67,880 | $0 The General Partner of the Issuer is entitiled to a management fee. | Benedetto Gartland & Company, Inc. BrokerCheck CRD 24083 ↗ via Benedetto Gartland & Company, Inc. (CRD 24083 ↗) |
| EDGAR ↗ | May 14, 2010 D File 021-142104 | $0 | $0 | $0 | None listed on this filing |
As reported by the issuer on Form D (Items 12–15), latest filing per offering (one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
Counted across every filing this person is listed on (latest filing per offering, per issuer).
| Source | Issuer | Role | Filed | Form | Offering | Sold | Investors | Min. investment |
|---|---|---|---|---|---|---|---|---|
| EDGAR ↗ | Palvella Therapeutics, Inc. | Director | Dec 30, 2022 | D | $37,704,498 similar: $2,000,000–$19,999,994 | $9,704,497 | 33 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Palvella Therapeutics, Inc. | Director | Jun 3, 2020 | D | $45,000,002 similar: $2,000,000–$19,999,994 | $45,000,002 | 48 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Molecular Templates, Inc. group: Molecular Templates | Director | Dec 3, 2019 | D/A | $14,999,994 similar: $2,000,000–$19,999,994 | $14,999,994 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Molecular Templates, Inc. group: Molecular Templates | Director | Nov 27, 2019 | D | $14,999,994 similar: $2,000,000–$19,999,994 | $14,999,994 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Velicept Therapeutics, Inc. group: Zoomi | Director | Nov 19, 2019 | D | $9,200,000 similar: $2,000,000–$19,999,994 | $6,000,000 | 5 similar: 2–16 | $1 similar: $10,000–$50,000 |
| EDGAR ↗ | Velicept Therapeutics, Inc. group: Zoomi | Director | Jul 18, 2018 | D | $15,624,000 similar: $1,694,259–$16,000,000 | $15,508,713 | 16 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Molecular Templates, Inc. group: Molecular Templates | Director | Aug 15, 2017 | D | $20,000,000 similar: $2,000,000–$19,999,994 | $20,000,000 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Molecular Templates, Inc. group: Molecular Templates | Director | Aug 15, 2017 | D | $40,000,000 similar: $2,000,000–$19,999,994 | $40,000,000 | 16 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Velicept Therapeutics, Inc. group: Zoomi | Director | Apr 20, 2017 | D/A | $26,300,003 similar: $1,694,259–$16,000,000 | $18,410,010 | 25 similar: 1–13 | $4,485 similar: $10,000–$55,000 |
| EDGAR ↗ | Velicept Therapeutics, Inc. group: Zoomi | Director | Dec 1, 2015 | D | $21,050,003 similar: $1,694,259–$16,000,000 | $12,028,576 | 24 similar: 1–13 | $4,485 similar: $10,000–$55,000 |
| EDGAR ↗ | Valence Advantage Life Sciences Fund II, L.P. group: Valence | Director Manager of the General Partner of the Issuer | Mar 14, 2013 | D/A | $175,000,000 | $60,800,000 | 11 | No minimum reported |
| EDGAR ↗ | Valence Advantage Life Sciences Fund II, L.P. group: Valence | Director Manager of the General Partner of the Issuer | Mar 14, 2012 | D | $175,000,000 | $0 | 0 | No minimum reported |
| EDGAR ↗ | Gemin X Pharmaceuticals Inc | Director | May 14, 2010 | D | $8,500,000 | $3,916,229 | 16 | No minimum reported |
Every row is a Form D or D/A on which the issuer listed this name as a related person. Related-person names are matched on first + last name and the address state on the filing; records that share a name but could not be tied together by a second identifier are listed separately below.
"Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Separate person records under the same name, not combined with this page. Each line says whether it is listed on an issuer this record is also listed on (a second identifier); where it is not, it could be the same person or a different one.
People and management entities the issuers listed as related persons on the same Form D filings as Scott Morenstein. Source: the EDGAR rows in the table above. Showing the 40 with the most shared filings.
None found in sources searched.
Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.
Export this report as PDF (members · included free during the launch period)
No corrections have been requested for this page.
Free. Logged with status: received → under review → fixed / confirmed with source.
If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.
Members get an email when Scott Morenstein appears on a new Form D, or when a court case or SEC action is matched to them. See plans →